Pallawi Torka1, Mathew Barth2, Robert Ferdman1, Francisco J Hernandez-Ilizaliturri3,4,5. 1. Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. 2. Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. 3. Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. francisco.hernandez@roswellpark.org. 4. Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. francisco.hernandez@roswellpark.org. 5. Department of Medicine, Jacob's School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY, USA. francisco.hernandez@roswellpark.org.
Abstract
PURPOSE OF REVIEW: Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival of cancer patients. This review focuses on the available data on mechanisms of resistance to rituximab and includes some additional information for other mAbs currently in use in hematological malignancies. RECENT FINDINGS: Mechanisms of resistance have been identified that target all described mechanisms of mAb activity including altered antigen expression or binding, impaired complement-mediated cytotoxicity (CMC) or antibody-dependent cellular cytotoxicity (ADCC), altered intracellular signaling effects, and inhibition of direct induction of cell death. Numerous approaches to circumvent identified mechanisms of resistance continue to be investigated, but a thorough understanding of which resistance mechanisms are most clinically relevant is still elusive. In recent years, a deeper understanding of the tumor microenvironment and targeting the apoptotic pathway has led to promising breakthroughs. Resistance may be driven by unique patient-, disease-, and antibody-related factors. Understanding the mechanisms of resistance to mAbs will guide the development of strategies to overcome resistance and re-sensitize cancer cells to these biological agents.
PURPOSE OF REVIEW: Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival of cancerpatients. This review focuses on the available data on mechanisms of resistance to rituximab and includes some additional information for other mAbs currently in use in hematological malignancies. RECENT FINDINGS: Mechanisms of resistance have been identified that target all described mechanisms of mAb activity including altered antigen expression or binding, impaired complement-mediated cytotoxicity (CMC) or antibody-dependent cellular cytotoxicity (ADCC), altered intracellular signaling effects, and inhibition of direct induction of cell death. Numerous approaches to circumvent identified mechanisms of resistance continue to be investigated, but a thorough understanding of which resistance mechanisms are most clinically relevant is still elusive. In recent years, a deeper understanding of the tumor microenvironment and targeting the apoptotic pathway has led to promising breakthroughs. Resistance may be driven by unique patient-, disease-, and antibody-related factors. Understanding the mechanisms of resistance to mAbs will guide the development of strategies to overcome resistance and re-sensitize cancer cells to these biological agents.
Authors: Kai Xue; Juan J Gu; Qunling Zhang; Cory Mavis; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman; Ye Guo Journal: J Cancer Res Clin Oncol Date: 2015-08-28 Impact factor: 4.553
Authors: John C Byrd; Shinichi Kitada; Ian W Flinn; Jennifer L Aron; Michael Pearson; David Lucas; John C Reed Journal: Blood Date: 2002-02-01 Impact factor: 22.113
Authors: Myron S Czuczman; Stephen Kahanic; Andres Forero; Glen Davis; Mihaela Munteanu; Eric Van Den Neste; Fritz Offner; Dominique Bron; Donald Quick; Nathan Fowler Journal: Ann Hematol Date: 2015-01-30 Impact factor: 3.673
Authors: Sean H Lim; Andrew T Vaughan; Margaret Ashton-Key; Emily L Williams; Sandra V Dixon; H T Claude Chan; Stephen A Beers; Ruth R French; Kerry L Cox; Andrew J Davies; Kathleen N Potter; C Ian Mockridge; David G Oscier; Peter W M Johnson; Mark S Cragg; Martin J Glennie Journal: Blood Date: 2011-07-18 Impact factor: 22.113
Authors: Isabelle Semac; Carmen Palomba; Karina Kulangara; Natacha Klages; Gerhild van Echten-Deckert; Bettina Borisch; Daniel C Hoessli Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Thomas Köhnke; Christina Krupka; Johanna Tischer; Thomas Knösel; Marion Subklewe Journal: J Hematol Oncol Date: 2015-10-08 Impact factor: 17.388
Authors: M Tommy Gambles; Jiahui Li; D Christopher Radford; Douglas Sborov; Paul Shami; Jiyuan Yang; Jindřich Kopeček Journal: J Control Release Date: 2022-09-05 Impact factor: 11.467
Authors: Suraya Elfrink; Martin Ter Beest; Luuk Janssen; Marijke P Baltissen; Pascal W T C Jansen; Angelique N Kenyon; Raymond M Steen; Daynelys de Windt; Philipp M Hagemann; Corine Hess; Dick-Johan van Spronsen; Brigiet Hoevenaars; Ellen van der Spek; Zijun Y Xu-Monette; Ken H Young; Charlotte Kaffa; Sander Bervoets; Jolien van Heek; Eva Hesius; Charlotte M de Winde; Michiel Vermeulen; Michiel van den Brand; Blanca Scheijen; Annemiek B van Spriel Journal: Blood Adv Date: 2022-04-12